Clinical Trial Update: Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a new adjunctive therapy to anti-VEGF for age-related macular degeneration; study completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Allergan adjunctive therapy to anti-VEGF

Snippet

Sponsor: Allergan | Conditions: Choroidal Neovascularization, Age-Related Maculopathy | Phase 2 | Status: COMPLETED | Results posted: 2012-09-03